Publication

Genomic Features of Response to Combination Immunotherapy in Lung Cancer

Journal Paper/Review - May 14, 2018

Units
PubMed
Doi

Citation
Früh M, Peters S. Genomic Features of Response to Combination Immunotherapy in Lung Cancer. Cancer Cell 2018; 33:791-793.
Type
Journal Paper/Review (English)
Journal
Cancer Cell 2018; 33
Publication Date
May 14, 2018
Issn Electronic
1878-3686
Pages
791-793
Brief description/objective

In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.